Home>Research>Research Progress

Scientists reveal the mechanism of rifampin inactivation by rifampin phosphotransferase

　　Rifampin (RIF), the best-known member of rifamycins, is a first-line drug for the treatment of tuberculosis, and also used to treat other bacterial infections. Extensive use of rifamycins has led to the development of bacterial resistances, which is